PANTHERx Rare Pharmacy Plans Collierville, Tennessee, Dispensing Operations
08/13/2024
The new facility will dispense 600,000 prescriptions over the next five years.
“A number of key factors made Collierville the perfect choice for our second pharmacy distribution center. These include Tennessee's business-friendly environment, bolstered by the governor's team and economic development staff; the invaluable support from Memphis and the Shelby County Chamber of Commerce; MLGW; and the highly skilled labor pool in the region,” David Loschinskey, Chief Operating Officer, PANTHERx Rare said.
PANTHERx Rare is a dual-accredited specialty pharmacy holding distinctions in rare disease including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence.?
“Healthcare is an integral part of the state’s economy, and today’s announcement will further strengthen our position as the center for this booming industry. I look forward to seeing PANTHERx® Rare’s success in the coming years and welcome this great brand to the Volunteer State,” noted TNECD Commissioner Stuart C. McWhorter.
Project Announcements
Momentous Expands Summit County, Utah, Operations
12/21/2025
Stryker Expands Salt Lake County, Utah, Operations
12/21/2025
Portal Space Systems Expands Bothell, Washington, Operations
12/21/2025
TerraForge Biocarbon Solutions Plans Magnolia, Mississippi, Operations
12/20/2025
Coastal Ready Mix Plans Conway, South Carolina, Production Operations
12/20/2025
PRET Advanced Materials Expands Johnsonville, South Carolina, Manufacturing Operations
12/19/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025